Intercept Pharmaceuticals Inc
NASDAQ:ICPT
Intercept Pharmaceuticals Inc
Gross Profit
Intercept Pharmaceuticals Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Intercept Pharmaceuticals Inc
NASDAQ:ICPT
|
Gross Profit
$317.1m
|
CAGR 3-Years
3%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$36.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$20.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$8.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
27%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$11.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
See Also
What is Intercept Pharmaceuticals Inc's Gross Profit?
Gross Profit
317.1m
USD
Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Gross Profit amounts to 317.1m USD.
What is Intercept Pharmaceuticals Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
14%
Over the last year, the Gross Profit growth was 15%. The average annual Gross Profit growth rates for Intercept Pharmaceuticals Inc have been 3% over the past three years , 14% over the past five years .